- Home
- ANTX vs LSB Comparison
ANTX vs LSB Comparison
Compare ANTX & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- LSB
- Stock Information
- Founded
- ANTX 2017
- LSB 2002
- Country
- ANTX United States
- LSB China
- Employees
- ANTX N/A
- LSB N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- LSB
- Sector
- ANTX Health Care
- LSB
- Exchange
- ANTX Nasdaq
- LSB NYSE
- Market Cap
- ANTX 37.3M
- LSB 31.5M
- IPO Year
- ANTX 2022
- LSB N/A
- Fundamental
- Price
- ANTX $1.20
- LSB $1.14
- Analyst Decision
- ANTX Buy
- LSB
- Analyst Count
- ANTX 4
- LSB 0
- Target Price
- ANTX $2.00
- LSB N/A
- AVG Volume (30 Days)
- ANTX 133.7K
- LSB 17.6K
- Earning Date
- ANTX 05-16-2025
- LSB 06-21-2025
- Dividend Yield
- ANTX N/A
- LSB N/A
- EPS Growth
- ANTX N/A
- LSB N/A
- EPS
- ANTX N/A
- LSB N/A
- Revenue
- ANTX N/A
- LSB $79,415,311.00
- Revenue This Year
- ANTX N/A
- LSB $39.33
- Revenue Next Year
- ANTX N/A
- LSB $75.61
- P/E Ratio
- ANTX N/A
- LSB N/A
- Revenue Growth
- ANTX N/A
- LSB N/A
- 52 Week Low
- ANTX $0.87
- LSB $1.15
- 52 Week High
- ANTX $3.07
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- ANTX 43.48
- LSB 28.76
- Support Level
- ANTX $1.05
- LSB $1.16
- Resistance Level
- ANTX $1.29
- LSB $1.28
- Average True Range (ATR)
- ANTX 0.07
- LSB 0.09
- MACD
- ANTX -0.00
- LSB 0.02
- Stochastic Oscillator
- ANTX 54.55
- LSB 0.00
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.